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abstract
PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007, provide
standardized definitions of adjuvant breast cancer clinical trial end points. Given the evolution of breast cancer
clinical trials and improvements in outcomes, a panel of experts reviewed the STEEP criteria to determine
whether modifications are needed.
METHODS We conducted systematic searches of ClinicalTrials.gov for adjuvant systemic and local-regional
therapy trials for breast cancer to investigate if the primary end points reported met STEEP criteria. On the basis
of common STEEP deviations, we performed a series of simulations to evaluate the effect of excluding non–
breast cancer deaths and new nonbreast primary cancers from the invasive disease–free survival end point.
RESULTS Among 11 phase III breast cancer trials with primary efficacy end points, three had primary end points
that followed STEEP criteria, four used STEEP definitions but not the corresponding end point names, and four
used end points that were not included in the original STEEP manuscript. Simulation modeling demonstrated
that inclusion of second nonbreast primary cancer can increase the probability of incorrect inferences, can
decrease power to detect clinically relevant efficacy effects, and may mask differences in recurrence rates,
especially when recurrence rates are low.
CONCLUSION We recommend an additional end point, invasive breast cancer–free survival, which includes all
invasive disease–free survival events except second nonbreast primary cancers. This end point should be
considered for trials in which the toxicities of agents are well-known and where the risk of second primary cancer
is small. Additionally, we provide end point recommendations for local therapy trials, low-risk populations,
noninferiority trials, and trials incorporating patient-reported outcomes.
J Clin Oncol 00. © 2021 by American Society of Clinical Oncology
INTRODUCTION
In 2007, a group of breast cancer experts from the
National Cancer Institute (NCI) and the National Clinical
Trials Network proposed standardized definitions for
efficacy end points in adjuvant breast cancer therapeutic
trials, widely known as the Standardized Definitions for
Efficacy End Points (STEEP). Their proposed end point
definitions are summarized in Table 1.1 The STEEP
criteria have since been used and referred to broadly in
breast cancer clinical trials. The expert panel that pro-
posed the original STEEP criteria endorsed invasive
disease–free survival (IDFS) as a less ambiguous end
point than disease-free survival (DFS), which had his-
torically varied significantly across trials in terms of the
events included. The definition for IDFS included inva-
sive local, regional, and distant recurrences; contralateral
breast cancer; second nonbreast primary cancer; and
death from any cause. IDFS was meant to specifically
exclude in situ cancer events (ipsilateral and/or con-
tralateral ductal carcinoma in situ [DCIS], lobular
carcinoma in situ [not deemed a preinvasive cancer],
and all in situ cancers of nonbreast sites). A separate end
point termed IDFS-DCIS was proposed for trials in which
inclusion of DCIS events was deemed appropriate.1
Breast cancer clinical trials and treatments have evolved
substantially since the STEEP criteria were established.
Advances include improved sensitivity of diagnostic
imaging, development of multiple immunohistochemis-
try markers that distinguish disease origin, and clinical
acknowledgment of the need for pathologic confirmation
of recurrence. In addition, improvements in breast
cancer management have decreased the risk of recur-
rence, leading to a relatively higher likelihood of death
from non–breast cancer causes in adjuvant trial
participants.2,3 Moreover, because of the improvements
in managing treatment-related toxicities and a commit-
ment to enrolling a group of patients more representative
of the actual affected population, patients enrolled in
clinical trials increasingly include older patients. These
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unrelated to their breast cancer or treatment. This evolution in
breast cancer treatment and outcomes led the NCI and
National Clinical Trials Network Breast Cancer Steering
Committee to convene an international group of experts to
reassess the STEEP criteria and to determine whether
modifications were needed. The panel focused on end points
for the adjuvant setting.
STEEP Adherence
We assessed utilization of STEEP criteria in phase III ad-
juvant trials published after January 1, 2008 (after the
original STEEP publication) with a completion date for the
primary analysis before January 1, 2020. Deviations from
STEEP definitions were discussed by the panel and these
deviations and discussions were used to inform the pro-
posed updated recommendations. The review was con-
ducted in ClinicalTrials.gov using the following search
criteria:
1. Breast cancer (for Condition);
2. Adjuvant (for Other terms);
3. Active, not recruiting, Suspended, Terminated, or
Completed (for Status); and
4. Phase 3 (for Study phase).
Of the resulting 83 trials, nonadjuvant trials, those without
primary efficacy end points, and those without a full
manuscript publication (because of inability to fully assess
end point definition) were excluded. The search yielded 11
adjuvant phase III breast cancer trials with primary efficacy
end points (Table 2).4-14 Of these, three had primary end
points that fully complied with the STEEP criteria, four used
STEEP definitions but not the corresponding end point
names (eg, used STEEP IDFS but called it DFS), and four
used definitions not included in the original STEEP
manuscript.
Since the initial search did not produce a comprehensive
list, we broadened our search to include all phase III ad-
juvant trials that had a primary efficacy end point, listed
results, and had a primary completion date between
January 1, 2010 and January 1, 2020 (Data Supplement,
online only).4-6,9,12,15-37 The resulting list is still not com-
prehensive but adequately reflects variability in end points
across trials and deviations from end point definitions.
Trials were divided into five categories: superiority, local
therapy, endocrine, low-risk population, and noninferiority
trials.
Superiority Trials
Most superiority trials either used or referenced a STEEP
definition and stated which events were not included (Data
Supplement). In trials that deviated from STEEP, the most
common deviation was exclusion of second nonbreast pri-
mary cancers. While developing the original STEEP guide-
lines, inclusion of second nonbreast primary cancer in the
IDFS definition was strongly debated, given the potential
disadvantage of including events that are not related to the
cancer or the treatment being studied, which might dilute the
efficacy effect. However, IDFS can identify events that may be
related to treatment, such as uterine cancer from tamoxifen.
Additionally, it avoids the potential problem of missing distant
recurrences that were erroneously diagnosed as new primary
cancers. Because second cancers are usually serious, often
affect overall survival (OS), and might not be distinguishable
from breast cancer or treatment-related events, the original
STEEP panel favored including them in the IDFS definition.
The three trials in our review that excluded second nonbreast
primary cancers all examined the addition of new targeted
therapies to standard chemotherapy and trastuzumab-based
therapy for early-stage breast cancer,5,6,9 and all three led to
US Food and Drug Administration (FDA) approval of the
agents in early-stage breast cancer.
Modeling the limitations of IDFS. Common wisdom sug-
gests that for time-to-event end points, such as IDFS or
recurrence-free interval (RFI), more events means more
power. However, having more events does not necessarily
translate to increased power and may decrease power
CONTEXT
Key Objective
Given the evolution of breast cancer clinical trials and improvements in outcomes, are modifications to the STEEP
criteria needed?
Knowledge Generated
An additional endpoint, invasive breast cancer-free survival, which includes all invasive disease-free survival events except
second nonbreast primary cancers, can be considered for trials in which the toxicities are well known and where risk of
second primary cancer is small. Additional end points for local therapy trials, low-risk populations, noninferiority trials,
and trials incorporating patient-reported outcomes are also included.
Relevance
The choice of a primary end point is critical for detecting a treatment effect and including events that have similar rates in the
treatment groups may dilute treatment differences and can increase the likelihood of a false inference of noninferiority.
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when some events included in the outcome have the same
rates in the two arms of the study and others have different
rates. To understand the potential impact of including
second nonbreast primary cancer diagnoses on the primary
end point that may or may not be related to disease or
treatment, simulations were performed that assumed a two-
arm study, comparing a standard-of-care (SOC) therapy
with an experimental therapy. Traditional IDFS was
compared with IDFS with second nonbreast primary can-
cers excluded; we termed this modified end point invasive
breast cancer–free survival (IBCFS). Figure 1 demonstrates
a superiority trial that aims to detect a 95% 3-year IBCFS in
the experimental arm versus 92% in the SOC arm (ie,
detection of a hazard ratio [HR] of 0.615 [red points]). This
trial has approximately 90% power with a sample size of
2,000 patients with a two-sided alpha of .05, assuming 3
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NOTE. Lobular carcinoma in situ is not included as an event in these definitions as it is not generally considered to be a direct precursor of breast cancer.
New definitions are shown in bold: (1) adjuvant trial end points were proposed in original STEEP, except for IBCFS; (2) local-regional therapy trial end points
were not proposed in the original STEEP. Adapted from original STEEP paper.1
Abbreviations: DCIS, ductal carcinoma in situ; DDFS, distant disease–free survival; DFS-DCIS, disease-free survival-ductal carcinoma in situ; DRFS, distant
relapse–free survival; IBCFS, invasive breast cancer–free survival; IBR, ipsilateral breast recurrence; IBR-DCIS, ipsilateral breast recurrence-ductal
carcinoma in situ; IBTR, ipsilateral breast tumor recurrence; IDFS, invasive disease–free survival; LRR, locoregional recurrence; OS, overall survival; RFI,
recurrence-free interval; RFS, recurrence-free survival; SCL, supraclavicular; STEEP, Standardized Definitions for Efficacy End Points.
aSite of first metastasis should be reported using the appropriate common data element term.
bThe term contralateral invasive breast cancer is preferred to second primary breast cancer as it is less ambiguous. Ipsilateral invasive breast cancers are
presumed to be a recurrence.
cSecond nonbreast primary cancers should not include squamous or basal cell skin cancers or new in situ carcinomas of any site.
dInterval signifies time from random assignment or registration to event.
eCan include in-breast recurrence or new primary after lumpectomy, chest wall recurrence after mastectomy, or both, depending on the patient population
specified in eligibility criteria.
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years of enrollment and 3 years of follow-up after the last
patient is enrolled.
To investigate the impact of second nonbreast cancers on
the IDFS end point, an annual rate of 1% was assumed for
this event in the SOC and 0.5%, 1%, and 2% in the ex-
perimental arms, respectively (Figs 1A-1C). Figure 1 shows
that the estimated HR for IBCFS is insensitive to these
events, even when the rates vary between the SOC and
experimental arms because of censoring event times for
these nonrecurrence events (ie, the HRs for the two sce-
narios are essentially the same for all three panels of Fig 1
for IBCFS). However, the HR for IDFS varies for different
rates of second primary diagnosis. Even when the rate of
second nonbreast cancers is the same in the SOC and
experimental arms (1%; Fig 1B), the HR is higher
(HR 5 0.71) and power is lower (81%) compared with
using IBCFS as the primary end point. Thus, adding events
to an end point will not necessarily increase the power: if the
event added has the same rate in the two treatment groups,
the inclusion of the event will dilute the treatment effect,
increasing the chance of a false-negative result. When the
rate in the experimental arm is higher (2%) than in the SOC
arm (1%), the power drops to 5% and the HR becomes
0.99 (Fig 1C). Conversely, when the rate in the
experimental arm is lower (0.5%), the power increases and
the HR moves further from 1 (power 5 99%; HR 5 0.58;
Fig 1A). Thus, if the event rate of second nonbreast cancers
differs in the two treatment groups (possibly because of
chance imbalances), the HR and the power will both be
affected, and IDFS will favor the arm with the lower rate.
This highlights the challenge of incorporating multiple
events in the same end point: it is not possible to distinguish
which events are driving the differences between arms.
Figure 1 reveals that inclusion (or exclusion) of events from
the primary end point can have a dramatic effect on in-
ferences in the trial, depending on the relative rates of these
events. When there is no difference in the event rates of
second nonbreast cancers between the SOC and experi-
mental arms, including them will dilute the observed effi-
cacy effect of interest and decrease the power. However,
excluding them could mask unanticipated toxicity effects,
and if excluded, toxicity effects should be considered as a
separate (secondary) end point to ensure differences in
treatment arms are identified if they exist (see the Data
Supplement regarding further implications on sample size).
Also shown in Figure 1 are analogous results to those
described above; but when a superiority trial assumes a 3-
year IBCFS of 72% versus 75% (blue points), the effects on
TABLE 2. Trials Identified in the Review of STEEP 1.0 Adherence









SOC 6 denosumab BMFS No No
APHINITY5 Targeted therapy Chemotherapy 1 trastuzumab 6 pertuzumab IDFSa No Yes
KATHERINE6 Targeted therapy Trastuzumab v T-DM1 IDFSa No Yes




NSABP B478 Targeted therapy Chemotherapy 6 trastuzumab IDFS Yes No
ExteNET9 Targeted therapy Trastuzumab 6 neratinib IDFSa No No









Docetaxel 1 trastuzumab (9 weeks) → FEC v
Docetaxel 1 trastuzumab (9 weeks) → FEC 1 trastuzumab





TITAN12 Chemotherapy Doxorubicin 1 cyclophosphamide → ixabepilone




Chemotherapy Cyclophosphamide 1 docetaxel 6 epirubicin IDFS Yes No
NSABP B-46-I14 Targeted therapy TC6, TAC6, or TC6 plus bevacizumab IDFS Yes No
Abbreviations: BMFS, bone metastasis–free survival; DFS, disease-free survival; DFS-DCIS, disease-free survival-ductal carcinoma in situ; FEC,
fluorouracil, epirubicin, and cyclophosphamide; GM-CSF, granulocyte-macrophage colony-stimulating factor; IDFS, invasive disease–free survival; NP-S,
nelipepimut-S; RFS, recurrence-free survival; SOC, standard of care; STEEP, Standardized Definitions for Efficacy End Points; TAC6,
docetaxel 1 doxorubicin 1 cyclophosphamide 36 cycles; TC6, docetaxel 1 cyclophosphamide 36 cycles; T-DM1, trastuzumab emtansine.
aIDFS indicates IDFS with second nonbreast primary cancer excluded.
bUsed the STEEP definition, but not the corresponding STEEP end point name.
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power and the estimated HRs trend in the same direction as
those in the previous example. However, the effects of
varying rates of second nonbreast cancers on the HR and
power are substantially lower, demonstrated by the much
smaller differences in IDFS versus IBCFS for the blue
versus the red points. Thus, trials that have low event rates
are particularly sensitive to the number and types of events
that are included in the primary end point.
Figure 2 provides analogous results to Figure 1 in a non-
inferiority de-escalation setting, demonstrating that an
event with a low rate can have a substantial effect on in-
ferences when the rate of recurrence is low, leading to an
increased chance of falsely inferring noninferiority when, in
fact, inferior effects of treatment have been masked by
inclusion of unrelated events (Data Supplement).
On the basis of our review and these results, IBCFS, which
includes all events in IDFS except second nonbreast cancers,
is proposed (Table 1). IBCFS has already been used in
numerous trials that have led to FDA approval of drugs in the
adjuvant setting and may be preferred over IDFS in superi-
ority trials if the intervention being assessed has been well-
studied in the population likely to be enrolled in the trial and is
known not to cause second nonbreast cancers. Second
nonbreast primary cancers should still be ascertained, and
standard IDFS should be reported as a secondary outcome.
The IBCFS end point should only be used in trials in which the
events that contribute to the primary and secondary out-
comes can be adequately adjudicated. If a trial is conducted
in lower-resource settings where imaging and other diag-
nostics cannot distinguish metastases from second non-
breast cancers, this end point is not optimal. Additionally, it is
important that long-term follow-up be conducted and re-
ported to better understand late events and toxicities and that
all STEEP end points be reported so that a better under-























1 1 1 1 1 1Second primary Dx rate in SOC group (%):
0.5 0.5 1 1 2 2Second primary Dx rate in Exptl group (%):
92 99 92 81 88 5Power (red; %):
89 98 89 88 89 11Power (blue; %):
IBCFS: 75% v 72%
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IBCFS: 75% v 72%
IBCFS: 95% v 92%
IBCFS: 75% v 72%




FIG 1. Comparison of IDFS versus IBCFS in the superiority design setting. Assumed new non-BC second primary cancer rate in the SOC arm is 0.01
annually and in the Exptl arm is (A) 0.005 (lower rate), (B) 0.01 (same rate), or (C) 0.02 (higher rate) annually. Two-sided a of .05 and 3 years of follow-up.
Data simulated under the two models. Red: hypothesis of 92% 3-year IBCFS (SOC) versus 95% (Exptl) (HR5 0.615); sample size of 1,000 per arm. Blue:
hypothesis of 72% 3-year IDFS without new non-BC second primary cancer events (SOC) versus 75% (Exptl) (HR5 0.876); sample size of 3,341 per arm.
BC, breast cancer; Dx, diagnosis; Exptl, experimental; HR, hazard ratio; IBCFS, invasive breast cancer–free survival; IDFS, invasive disease–free survival;
SOC, standard of care.
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Local Therapy Trials
To understand the typical end points used in adjuvant local
therapy trials, we searched ClinicalTrials.gov for local
therapy trials using the following search criteria:
1. Breast cancer (for Condition);
2. Adjuvant (for Other terms);
3. Active, not recruiting, Suspended, Terminated, or
Completed (for Status); and
4. Phase 3 (for Study phase).
Since these types of trials and end points were not dis-
cussed in the original manuscript, we extended this search
to trials that started on or after January 1, 1999 and had
primary completion on or before January 1, 2020. Of the
181 trials identified, only three were local therapy trials:
RTOG-9804,38 ACOSOG-Z0011,39 and APBI-IMRT-
Florence.40 The primary end points were ipsilateral breast
tumor recurrence (IBTR), 10-year OS, and 5-year IBTR,
respectively (Table 3).38-40 As this search did not yield a
comprehensive list, we reviewed a wider collection of ad-
juvant phase III local therapy trials in breast cancer (Data
Supplement).38,41-52
Surgical and radiotherapy trials. As improvements in sys-
temic therapy have reduced the risk of distant recurrence,
many recent trials have focused on optimizing local
therapy. These include randomized trials of whole-breast
radiotherapy (RT) versus observation following breast-
conserving therapy,38,49 whole-breast versus partial-breast
RT,42,46,48 and local excision versus observation41,43-45,47,50,51
(Data Supplement). For these trials, IBTR was the predom-
inant primary end point. The composite end point IBTR does
not allow discrimination of histologic type (invasive or DCIS) or
location of in-breast recurrence. We, therefore, recommend
alternative locoregional end points that differentiate these
events (Table 1). These end points will provide more infor-
mative data on cancer progression and therapeutic effect (eg,


















1 1 1 1Second primary Dx rate in SOC group (%):
0.5 0.5 1 1Second primary Dx rate in Exptl group (%):
38 > 99 38 91Power (red; %):
46 97 43 57Power (blue; %):
IDFSIBCFS IDFSIBCFS
IBCFS: 75% v 73.5%
IBCFS: 95% v 93.5%
IBCFS: 75% v 73.5%
IBCFS: 95% v 93.5%
A B
FIG 2. Comparison of IDFS versus IBCFS in the noninferiority, de-escalation design setting. Assumed new non-BC second primary cancer rate in the SOC
arm is 0.01 annually and in the Exptl arm is (A) 0.005 (lower rate) or (B) 0.01 (same rate) annually. Five years of follow-up; inference on the basis of upper
limit of 90% CI for HR. Data simulated under the two models. Red: hypothesis of 95% 5-year IBCFS (SOC) versus 93.5% (Exptl) (HR5 1.31); sample size
of 1,000 per arm. Blue: hypothesis of 75% 5-year IDFS without new non-BC second primary cancer events (SOC) versus 73.5% (Exptl) (HR 5 1.07);
sample size of 2,750 per arm. BC, breast cancer; Dx, diagnosis; Exptl, experimental; HR, hazard ratio; IBCFS, invasive breast cancer–free survival; IDFS,
invasive disease–free survival; SOC, standard of care.
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We recommend a new composite end point, ipsilateral
breast recurrence (IBR), defined as the development of a
subsequent invasive breast cancer (either a recurrent
cancer or a new primary) or DCIS in the ipsilateral breast or
on the chest wall (Table 1). The terms IBR-invasive and
IBR-DCIS can be used in trials where distinguishing in-
vasive from DCIS local recurrences is critical. The quadrant
location of both the primary and recurrence should be
recorded if feasible, to distinguish between recurrences
within or outside of the tumor bed, or outside of the radiated
field. Contralateral breast tumor recurrence, including in-
vasive cancer and DCIS, should continue to be recorded as
a separate locoregional end point, and a competing risks
approach for analysis should be considered.
Regional nodal treatment. Randomized trials of regional
nodal treatment include trials of nodal RT versus none and
trials of axillary nodal dissection versus nodal RT, either in
the adjuvant setting or following neoadjuvant treatment.
Although some reported trials used end points contained
within STEEP 1.0, the panel recommends including an
additional end point: regional nodal recurrence, defined as
tumor recurrence in lymph nodes in the ipsilateral axilla,
supraclavicular fossa, or internal mammary region. We also
recommend explicitly indicating the location of the nodal
recurrence where possible. We propose the inclusive end
point locoregional recurrence to include ipsilateral breast or
chest wall recurrence of invasive cancer or DCIS and any
ipsilateral recurrence in these nodal groups. These end
points are particularly relevant for trials of de-escalation of
axillary nodal surgery.
Endocrine Therapy Trials
Endocrine therapy trials were given special consideration in
the original guidelines, which noted inconsistencies in the
definition of DFS among adjuvant trials comparing aro-
matase inhibitors with tamoxifen. Since the incidence of
contralateral breast primaries is altered by endocrine
therapy, it is important to include these in the primary end
point to adequately characterize the benefits of the treat-
ment. However, these events may not be as important as
distant recurrences to different groups of patients. For
example, those who have had bilateral mastectomies are
generally not considered to be at sufficient risk of a con-
tralateral primary breast cancer for that benefit to justify
therapy. Patients who experience symptomatic toxicities
may decline to continue therapy if it does not prevent a
distant recurrence. Thus, as was noted in the original
guidelines,1 publications should include a table detailing
the prevalence of event type (ipsilateral, contralateral, and
distant) by study arm. This allows for clinicians to indi-
vidualize the discussion of risks and benefits of the inter-
vention for a patient’s clinical situation and treatment goals.
Low-Risk Populations
When the anticipated event rate in a treated population is
low, a randomized trial may not be feasible given the large
sample size that would be required to demonstrate a
treatment effect. If historical data exist for the anticipated
event rate with the standard of care, a single-arm trial that
identifies a clinically acceptable event rate with a new
treatment may be acceptable.
Two recent examples of single-arm trial designs that
influenced the standard of care for early-stage breast
cancer are the low-risk arm of TAILORx53 and APT.54,55 In
TAILORx, on the basis of robust retrospective data that
failed to demonstrate a benefit for adjuvant chemotherapy
in patients with low Oncotype Dx recurrence score,56 pa-
tients with a recurrence score of 0-10 were treated with
endocrine therapy alone. These patients had a 5-year IDFS
of 93.8% (95%CI, 92.4 to 94.9) and RFI of 99.3% (95%CI,
98.7 to 99.6),53 confirming endocrine therapy alone as the
preferred treatment and the dominance of non–breast
cancer events in such a population.
Similarly, the APT trial prospectively assessed whether a
systemic therapy regimen (paclitaxel and trastuzumab)
was associated with a clinically acceptable event rate in
patients with small, node-negative human epidermal
growth factor receptor 2–positive breast cancers. This trial
demonstrated a 7-year IDFS of 93% (95% CI, 90.4 to 96.2)
and a 7-year RFI of 97.5% (95% CI, 95.9 to 99.1).54,55
Although the APT study cannot conclude that treatment
with paclitaxel and trastuzumab is better than no therapy,
the low event rate suggests that escalating therapy by using
more intensive regimens, such as those administered in the
pivotal adjuvant studies, is unlikely to produce better
outcomes.
When choosing an end point for a trial in patients at a
relatively low risk of distant or local recurrence, it is im-
portant to acknowledge that IDFS captures events such as
new contralateral primary breast cancers and deaths from
other causes that do not reflect a recurrence of the initial
breast cancer. With long follow-up, the frequency of these
events increases, and their occurrence may dilute the
TABLE 3. Local Therapy Trials Identified in ClinicalTrials.gov
Trial Type of Intervention Study Arms Primary End Point
RTOG-980438 Radiation Optional tamoxifen 6 whole-breast RT IBTR
ACOSOG-Z001139 ALND Whole-breast RT 6 ALND 10-Year OS
APBI-IMRT-Florence40 Radiation Whole-breast RT v accelerated partial-breast RT 5-Year IBTR
Abbreviations: ALND, axillary lymph node dissection; IBTR, ipsilateral breast tumor recurrence; OS, overall survival; RT, radiation therapy.
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effect of treatment on the end point. RFI, which includes
invasive locoregional and distant recurrences and deaths
as a result of breast cancer (but not contralateral breast
cancer, second nonbreast primary cancers, and non–
breast cancer death), may better describe the relevant
event rate in this patient population and should be con-
sidered in these settings. However, we acknowledge that in
older patient populations, a comparison of all-cause mor-
tality may also be relevant, to provide context for cancer-
specific mortality. To evaluate the impact of including non–
breast cancer deaths in low-risk patient populations,
simulations were performed similar to those shown in
Figure 1 (Data Supplement).
If RFI is used as the primary end point, IDFS should still be
presented as a secondary end point since it has the ad-
vantage of potentially uncovering previously unidentified
treatment toxicities.
Noninferiority Trials
Noninferiority trials are designed to demonstrate that an
alternative treatment is not less effective than a standard
treatment by a prespecified amount (noninferiority margin).
This trial design has been increasingly used to assess
treatment de-escalation, either by using a new, less toxic
agent or by assessing a shorter duration of therapy or
omission of a treatment modality.
Critical to the design of noninferiority trials is the identifi-
cation of a clinically acceptable noninferiority margin.
Noninferiority trials should include careful adverse event
reporting, especially if outcomes are similar in trial arms, as
the adverse event profile may be essential for making
treatment decisions. Historically, cross-trial comparison
has been complicated by the use of different end point
definitions and noninferiority thresholds in different trials
conducted in similar populations. The MINDACT57 trial and
the randomized portion of TAILORx22 both assessed
whether chemotherapy could be omitted in patients de-
fined by a genomic profile; however, the studies used
different primary end points (5-year IDFS in TAILORx;
distant metastasis–free survival in MINDACT) and different
thresholds. Both trials achieved results well within the
specified noninferiority thresholds, but it is difficult to
compare results since different end points and non-
inferiority thresholds were used (Table 4).
Modeling the limitations of IDFS. As demonstrated in
Figure 2 and described above, events with low rates can
affect estimation of HRs and the effects are more dramatic
in low-risk populations, leading to increased chance of
falsely concluding noninferiority when unrelated events are
included in end point definitions. Noninferiority trials are
particularly relevant in low-risk populations as the avoid-
ance of toxicity is more important when the expected risk of
recurrence is low. Thus, as above, consideration of IBCFS
or RFI as the primary end point may be warranted so that
events captured are a true reflection of therapy adminis-
tered. Comparisons of RFI and RFS in the noninferiority, de-
escalation design setting are shown in the Data Supple-
ment. The results are similar to those for comparing IDFS
and IBCFS.
Patient-Reported Outcomes as a Trial End Point
An important goal in a randomized controlled trial of ad-
juvant therapy is to provide clinically relevant information
that can inform shared decision making. Including patient-
reported outcome (PRO) assessments in clinical trials can
provide information about a patient’s health that is im-
portant in discussions between patients and their clini-
cians. Validated PRO assessments that can help inform
decision making should be included whenever possible.
For example, PRO-Common Terminology Criteria for Ad-
verse Events can be used to assess symptomatic adverse
events to measure safety and tolerability from patients’
perspectives.58 Furthermore, if PROs are critical to the
overall trial objectives, the study should be designed to
accommodate them. For example, a PROmay be classified
as a co-primary rather than secondary end point, with the
type I error divided between primary end points. Impor-
tantly, PRO results should be reported concurrently with
efficacy results so that both sets of results may be inter-
preted together to provide a balanced evaluation of ad-
vantages and disadvantages to each arm of a trial. This is
particularly vital in noninferiority studies where patients and
their clinicians will need to weigh the possible loss of ef-
ficacy against the potential gain in quality of life.
Regulatory Considerations
The primary end point of an oncology clinical trial can serve
different regulatory purposes (eg, a clinical end point that
represents clinical benefit for regular or traditional approval,
such as OS; a surrogate end point to support traditional
approval, such as IDFS; or a surrogate end point to support
an accelerated approval, such as overall response rate).
The determination is generally based on the specific dis-
ease and is dependent on factors such as effect size,
available therapy, disease setting, and the risk-benefit re-
lationship. Historically, the use of IDFS as the primary end
point in adjuvant breast cancer trials has conferred ad-
vantages, but it is also subject to important disadvantages
as discussed above. Furthermore, the definition of IDFS
has varied among trials, and it includes non–breast cancer
deaths and second nonbreast primary cancers. The FDA
has released a guidance for sponsors to select appropriate
end points for oncology trials that will support marketing
applications.59 It is recommended that sponsors meet with
the FDA before submitting protocols intended to support a
new drug or biologics license marketing application. The
FDA has advised that they will ensure that these meetings
include a multidisciplinary team of oncologists, statisti-
cians, clinical pharmacologists, and external expert con-
sultants as needed. Sponsors can request a special
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protocol assessment that provides confirmation of the
acceptability of study design and end points to support drug
marketing applications.
SUMMARY
The original STEEP criteria were established for adjuvant
breast cancer trials, recognizing that it is critical to select
the appropriate multievent end point to describe treatment
benefits and risks and to allow for cross-trial comparisons.
This article addresses end points for phase III trials of either
adjuvant or local-regional therapy trials for patients with
breast cancer. We did not consider end point selection for
trials assessing neoadjuvant breast cancer therapies, or
adjuvant therapy after neoadjuvant therapy, which were
reviewed by Fumigalli et al60 in an effort led by the Breast
International Group and the NCI-sponsored North Ameri-
can Breast Cancer Group. However, we think our proposed
revision of adjuvant trial end points could be applicable to
longer-term end points of such studies.
The simulations described in this article illustrate that the
choice of primary end point is critical for detecting a treat-
ment effect and raise several important points to consider:
1. When choosing an end point that includes multiple
events, it is often difficult to identify which events are
driving the estimated HR. Even if the HR is close to 1, it
cannot be inferred that the treatments have similar
efficacy and toxicity effects—in fact, these could be
offsetting each other, with one treatment having higher
toxicity yet lower efficacy than the other.
2. Including events that have the same or similar rates in
treatment groups will compromise power and may
dilute other treatment differences in superiority trials.
In noninferiority trials, it can increase the likelihood of
false inference of noninferiority.
3. When events of interest are relatively rare, the impact
of including events that are unaffected by treatment is
more substantial. However, in situations when events
are rare, it is risky to assume, rather than test, whether
or not the events may be treatment related.
When agents being studied have well-known toxicity pro-
files and have been shown not to increase the risk of death,
occurrence of second nonbreast primary cancers, or other
serious adverse events, IBCFS and RFI should be con-
sidered as alternatives to IDFS. When choosing an ap-
propriate end point, characteristics of the population being
studied, including comorbidities and competing risks,
should be considered. Regardless of the primary end point,
data pertaining to both IDFS and IBCFS (or other relevant
complementary end points) should be captured and re-
ported in study results, with clear rationale of which end
point was a priori selected as the primary end point. RFI,
which includes invasive locoregional and distant recur-
rences and breast cancer–related deaths, may better de-
scribe the relevant event rate in low-risk patient populations
and thus should be used in these settings. Inclusion of at
least one other STEEP end point in a secondary objective is
essential to understand how treatments affect different end
points. Additionally, it is important for trials to have long-
term follow-up not only to understand efficacy over time but
also to evaluate late toxicities. Finally, inclusion of appro-
priately measured and powered PROs, and timely reporting
of their results, ideally concurrently with the efficacy end
points, is important to ensuring that study results may be
used to best inform clinical decisionmaking by patients and
their doctors.
TABLE 4. Important Considerations by Type of Trial
Trial Type Considerations
Superiority trials IBCFS may be preferred over IDFS if the intervention being assessed has been well-studied in the population likely to
be enrolled in the trial and is known not to cause second nonbreast cancers
Second nonbreast primary cancers should still be ascertained, and standard IDFS should be reported as a secondary
outcome
The IBCFS end point should only be used in trials in which the events that contribute to the primary and secondary
outcomes can be adequately adjudicated
Endocrine therapy trials DFS is a reasonable end point, but it is critical to provide breakdown of the prevalence of each type of event (ipsilateral,
contralateral, and distant) by study arm
Low-risk trials RFI may better describe the relevant event rate in this patient population and should be considered, and IDFS should
also be reported
Noninferiority trials Consideration of IBCFS or RFI as the primary end point may be warranted so that the events captured are a true
reflection of the therapy administered
IDFS should also be reported
Breast surgery and radiation
therapy trials
Consider IBR as the primary end point (see Table 1 for local-regional therapy end points)
Abbreviations: DFS, disease-free survival; IBCFS, invasive breast cancer–free survival; IBR, ipsilateral breast recurrence; IDFS, invasive disease–free
survival; RFI, recurrence-free interval.
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